OncoMatch/Clinical Trials/NCT06232655
Cladribine Venetoclax in Monocytic AML
Is NCT06232655 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cladribine and Venetoclax for acute myeloid leukemia.
Treatment: Cladribine · Venetoclax · Azacitidine — Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: hypomethylating agent and venetoclax combination
relapsed after or refractory to prior treatment with hypomethylating agent (HMA) and venetoclax combination
Cannot have received: cladribine (cladribine)
Subject has received prior treatment with cladribine for AML.
Lab requirements
Kidney function
calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021)
Liver function
AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome; in subjects with Gilbert's syndrome, bilirubin ≤ 4 x ULN
Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021). Adequate liver function, as demonstrated by: AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome; in subjects with Gilbert's syndrome, bilirubin ≤ 4 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Universtiy of Colorado Hospital · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify